Arrogene’s Chief Scientific Officer and co-founder, Julia Ljubimova, MD, PhD, has received a $2.8 million grant from he National Cancer Institute of the National Institutes of Health to advance her research of tumor nanoimmunology to treat cancers of the brain, breast, lung and other organs. “Our goal is to improve the body’s immune system so it can block tumors from forming,” Ljubimova said. “This new grant will allow us to continue developing a new generation of drugs that will have the ability to improve the pharmaceutical and pharmacologicalproperties of anti-cancer drugs, increase the efficacy of cancer treatment and deliver multiple types of therapeutics for combination therapy.” (more…)
Arrogene, Inc., a biotechnology company developing nano-diagnostic and therapeutic agents based on natural polymer and beta-polymalic acid, has announced that Dr. Jack Kavanaugh, a widely respected executive who has successfully led and guided multiple biotech and physical science companies, will assume the title of Chairman and Executive Chairman effective immediately.
Arrogene’s technology was developed at Cedars-Sinai Medical Center under the leadership and guidance of Julia Ljubimova, MD, PhD, director of the Nanomedicine Research Center in the Maxine Dunitz Neurosurgical Research Institute at Cedars-Sinai and founder and lead scientist at Arrogene. (more…)
Arrogene scientists are featured in an article about new targeted therapies to fight breast cancer. Reporter Kim Lamb Gregory interviewed Arrogene co-founder and Chief Scientific Officer: “Dr. Julia Ljubimova and her research team are testing a family of drugs for HER2- positive metastatic breast cancer called Polyolefin. The drug is nanoscale Trojan Horse that sneaks into the cancer cell carrying a variety of weapons that stage a multipronged attack on the cancer, including Perception.”
Arrogene scientists publish new research breakthrough, and it’s getting a lot of attention in the press. As detailed in ACS Nano, they used nano imaging agents for differential diagnostics of tumor metastases to the brain. The research received coverage in Health Management, Science News Line, Radiology Business, and Phys.org.
Arrogene’s biomedical researchers have invented a tiny drug-delivery system that can identify cancer cell types in the brain through “virtual biopsies” and then attack the molecular structure of the disease. If laboratory research with mice is borne out in human studies, the results could be used to deliver nano-scale drugs that can distinguish and fight tumor cells in the brain without resorting to surgery. “Our nanodrug can be engineered to carry a variety of drugs, proteins and genetic materials to attack tumors on several fronts from within the brain,” said Arrogene’s co-founder, Julia Ljubimova, MD, PhD, professor of neurosurgery and biomedical sciences at Cedars-Sinai and a lead author of an article published online in the American Chemical Society’s journal ACS Nano.